Silent sinus syndrome with interfrontal sinus retraction: A 3-case series using CARE methodology.

INTRODUCTION: Silent sinus syndrome (SSS) is a rare entity, almost exclusively involving the maxillary sinus, frontal location being very rarely reported. The aim of the present study was to describe clinical and radiological characteristics and surgical treatment using the CARE methodology. RESULTS: One woman and 2 men were referred for chronic unilateral frontal pain with imagery showing silent sinus syndrome. All showed partial or complete liquid opacification of the affected sinus associated with a thin interfrontal sinus (IFS) retracted toward the affected sinus. Functional endoscopic sinus surgery was performed in all cases, with good functional results. DISCUSSION: We describe 3 cases of SSS with IFS involvement. The frontal sinus wall seemed most vulnerable, probably most liable to be weakened by atelectasis. The study suggests that frontal SSS can be an etiology in chronic frontal sinusitis. Preoperative findings of IFS retraction are useful for surgical restoration of frontal sinus ventilation, relieving chronic pain and preventing complications.

Sensorineural hearing loss in patients with vestibular schwannoma correlates with the presence of utricular hydrops as diagnosed on heavily T2-weighted MRI.

PURPOSE: The purpose of this study was to assess whether the volume of the vestibular endolymphatic space correlates with the degree of hearing loss using heavily T2-weighted fast imaging employing steady-state acquisition with cycle phase (FIESTA-C) MRI. MATERIALS AND METHODS: A total of 23 patients with vestibular schwannoma, as diagnosed on typical image findings, who underwent FIESTA-C MRI were included. There were 13 women and 10 men with a mean age of 63.5±9.3 (SD) years (range: 49-88years). Two radiologists independently evaluated the volume of the utricle and saccule. Correlation between tumor volume, vestibular endolymphatic space volume and degree of hearing loss - as evaluated with the levels of pure-tone average and speech recognition threshold - were searched for. RESULTS: The mean saccular, utricular and tumor volumes were 3.17±1.1 (SD) mm3 (range: 1.45-5.7mm3), 14.55±5 (SD) mm3; (range: 6.6-23.9mm3) and 17.4±5.5 (SD) mm3; (range: 8.3-25.4mm3), respectively. There was a moderate correlation between the volume of the utricle and the degree of hearing loss as evaluated with the levels of pure-tone average (rho=0.5; P=0.015) and speech recognition threshold (rho=0.58; P=0.004). There were no significant correlations between saccular and tumor volumes and the degree of hearing loss. CONCLUSION: The volume of the utricle in patients with obstructive vestibular schwannoma moderately correlates with the degree of hearing loss.

Comparison of enhancement of the vestibular perilymph between gadoterate meglumine and gadobutrol at 3-Tesla in Meniere's disease.

PURPOSE: To compare the degree of enhancement of the perilymph between two macrocyclic gadolinium-based contrast agents (gadobutrol and gadoterate meglumine) in patients with Meniere's disease at 3-T magnetic resonance imaging (MRI). MATERIALS AND METHODS: The MRI examinations of 20 patients with Meniere's disease obtained 4hours after a single intravenous dose of macrocyclic gadolinium-based contrast agents were retrospectively compared. Ten patients (median age: 58.5 years; median body mass index [BMI]: 25) have received a single intravenous dose of gadoterate meglumine and 10 patients (median age: 45.5 years; median BMI: 25.4) have received a single-dose of gadobutrol. Two radiologists independently measured the signal intensity ratio (SIR) by using region of interest analysis and performed a visual assessment in order to evaluate the perilymph of each semicircular canal and of the vestibule. RESULTS: No differences in SIR of the symptomatic ear were found between gadobutrol (median SIR: 1.58) and gadoterate meglumine (median SIR: 1.3) (P=0.18). The SIR of the contralateral asymptomatic ear was significantly greater with gadobutrol (median: 1.62) than with gadoterate meglumine (median: 1.21) (P=0.009). No differences in endolymphatic structures visualization were found between gadobutrol and gadoterate meglumine in the symptomatic ears (P=0.27) but gadobutrol allowed a better assessment of endolymphatic structures and semicircular canals in the asymptomatic ear (P<0.001). CONCLUSION: Gadobutrol and gadoterate meglumine provide similar degrees of enhancement of the symptomatic ear in patients with Meniere's disease but gadobutrol provides better anatomical details regarding endolymphatic space and semicircular canals of asymptomatic, contralateral ear.